Vigil Neuroscience(US:VIGL)2025-05-07 11:15Financial Performance - Cash, cash equivalents, and marketable securities were $87.1 million as of March 31, 2025, down from $97.8 million as of December 31, 2024[7] - Net loss for Q1 2025 was $22.4 million, compared to a net loss of $19.9 million in Q1 2024[7] - Total operating expenses for Q1 2025 were $23.5 million, compared to $21.4 million in Q1 2024[12] - General and Administrative (G&A) expenses for Q1 2025 were $7.0 million, consistent with $7.1 million reported in Q1 2024[7] - Research and Development (R&D) expenses for Q1 2025 were $16.5 million, an increase from $14.3 million in Q1 2024, driven by higher preclinical and manufacturing costs[7] - The company expects its cash runway to be sufficient to fund operations into 2026[9] Clinical Trials and Developments - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is planned for Q2 2025, with an accelerated approval pathway being pursued[3] - VG-3927 showed a robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid, demonstrating strong pharmacokinetics and pharmacodynamics[5] - The Phase 2 clinical trial for VG-3927 in Alzheimer's disease is expected to be initiated in Q3 2025[2] - The company plans to advance a once-daily oral dose of 25 mg of VG-3927 that fully engages the desired pharmacology[5]